PhRMA

NEW: IQVIA released a new study exposing a patient medicine denial crisis. 🚨 7️⃣0️⃣% of patients seeking branded medicines through commercial insurance were initially denied coverage, forcing patients to give up on their medicines or navigate a maze of appeals. Delays like that can have serious consequences for health outcomes. Learn more about the denial crisis ➡️ phrma.org/blog/70-denied…

Amgen’s latest $300 million investment in U.S. manufacturing brings its total to nearly $2 billion over the past year, strengthening supply chains and supporting American jobs. Investments like this show how a strong U.S. innovation ecosystem helps drive biopharmaceutical leadership, improve patient access and fuel economic growth. Policies that support innovation are key to sustaining this progress. Read more: ow.ly/GTH850YVeko

Congratulations to our own @steveubl and @lreilly71 on being named to @washingtonian's “500 Most Influential People in Washington, D.C.” list. 👏 Their leadership helps drive innovation and expand access for patients. washingtonian.com/2026/05/05/was…

Maintaining U.S. leadership in life sciences requires action. Our CEO, @steveubl, joined @CNBC to talk about what action is needed: 🧪 More efficient clinical trials 🚧 Fewer barriers from PBMs and insurers 🧬 Policies that support investment in innovation The decisions we make today will determine whether America continues to lead. #InvestInAmericaForum #cnbcevents

Nearly 1 in 4 Americans—including 1 in 5 children—live with a mental health condition, yet only about half of adults seek treatment. The good news: treatment works. Medications, often paired with therapy, can improve outcomes, reduce relapses, and prevent hospitalizations. Learn more at PhRMA.org/MentalHealth

The @WashingtonPost Editorial Board is the latest to join the chorus of voices calling for federal reform of the 340B Program. Unchecked growth has turned 340B into a profit center for large hospital systems, driving up costs for everyone else.

MFN would weaken innovation, siphon billions from R&D and lead to hundreds of fewer lifesaving treatments and cures. This hurts patients, especially the patients and their families who are waiting on cures for life-threatening or rare diseases. Policymakers must reject MFN and protect cures for American patients. ow.ly/5TBE50YTelE

The future of medicine is expanding fast. Scientists may soon be able to discover cures 10 or even 100 times faster than they can today.

Patients care about getting the medicines they need. But where those medicines are developed matters. U.S. leadership means faster access for patients, high-value jobs and stronger national and economic security. We can’t afford to fall behind. #InvestInAmericaForum #cnbcevents

America’s biopharmaceutical leadership fuels more than just medicine breakthroughs. The biopharmaceutical industry fuels jobs, investment and economic growth in every state. ow.ly/bbVZ50YSv7J

April marks #MedicaidAwarenessMonth, a time to recognize the vital role Medicaid plays in providing health coverage for nearly one in five Americans. Nearly 800 Biopharmaceutical manufacturers participate in Medicaid in all 50 states, working within the program to help ensure our most vulnerable patient populations can access innovative medicines. Learn more: phrma.org/medicaid?utm_s…

For many physicians today, some of the most serious infectious diseases are no longer part of daily practice. That is the result of decades of progress in vaccination. But maintaining that progress takes ongoing commitment. As vaccination rates shift and new challenges emerge, it is critical to sustain the policies and investment that support continued innovation and patient protection. Read more: ow.ly/4XlU50YROM8

Today, health system CEOs testify before the Ways & Means Committee. What's sure to be on the agenda: hospital consolidation. It isn't just a market trend – hospital consolidation is fueled by perverse incentives in the 340B program. Get caught up here: phrma.org/blog/a-program…

Babies are not given over 80 vaccines at once. The childhood schedule protects against 16 diseases and does not overload the immune system. Vaccines help protect babies when they’re most vulnerable to serious illnesses like measles and polio. phrma.org/vaccines

Too often in research, scientists unknowingly repeat the same experiments and lose valuable time. With AI and human expertise working together, we can reduce duplication, improve efficiency and help bring new treatments to patients faster.

Strong IP protections help drive the innovation that improves lives, including in sports medicine. From managing chronic respiratory conditions to supporting recovery from injuries, medical advances play an important role in helping athletes stay healthy and return to play safely. On World IP Day, we recognize how policies that support innovation continue to enable new treatments and expand what is possible for patients and athletes alike. phrma.org/IP

Minnesota’s own data shows the problem with the 340B hospital markup program: Hospitals made $1.3B+ in 340B profits—nearly $1B more than they spent on uncompensated care. If patients aren’t benefiting, where is the money going? Transparency and accountability are long overdue. drugchannels.net/2026/04/minnes…

America’s biopharmaceutical industry drives jobs, investment and innovation. $500B in new U.S. investments. Global leadership in R&D. Most new medicines launch here first. With rising competition, policy decisions will determine if the U.S. continues to lead. #InvestInAmericaForum #cnbcevents

On the Hill this week, we heard how insurers are standing between patients and care. New data shows 70% of patients are initially denied coverage for a prescribed medicine, delaying or preventing treatment. Patients should not face red tape. It is time to put them first. phrma.org/blog/briefing-…

Vaccines are one of the most effective tools to prevent disease and protect patients, and their impact is especially recognized during World Immunization Week. But continued progress depends on maintaining strong vaccination rates and advancing a science-based policy environment that supports innovation and access. Learn more from Dr. Mike Ybarra: phrma.org/blog/world-imm…

In honor of National Supply Chain Integrity Month, did you know that 70% of medicines are approved here in the U.S. first? And 2/3 of the medicines consumed in the U.S. are made here at home as well. America’s leadership in innovation supports a healthier future and a more secure nation.